Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Formycon AG (FYB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
43.20 +2.20    +5.37%
01:36:18 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 25,965
  • Bid/Ask: 43.30 / 43.80
  • Day's Range: 41.35 - 43.80
Type:  Equity
Market:  Germany
ISIN:  DE000A1EWVY8 
WKN:  A1EWVY
Formycon 43.20 +2.20 +5.37%

Formycon AG Company Profile

 
Get an in-depth profile of Formycon AG, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

224

Equity Type

ORD

Formycon AG develops and markets biosimilar products in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema and myopic choroidal neovascularization under the Ranivisio, ONGAVIA, and CIMERLI names. The company’s pipeline includes FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of chronic inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea, that treats neovascular age-related macular degeneration and serious retinal diseases that is in Phase III clinical trials. It is also developing FYB206, a biosimilar candidate for Keytruda, for the treatment of cancer; and FYB207, a SARS-CoV-2 blocker, an antiviral drug for the treatment of COVID-19. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

Contact Information

Address Fraunhoferstrasse 15 Martinsried
Planegg, 82152
Germany
Phone 49 89 864 667 100
Fax 49 89 864 667 110

Top Executives

Name Age Since Title
Peter Wendeln - 2010 Deputy Chairman of Supervisory Board
Olaf Stiller 45 2010 Chairman of Supervisory Board
Johannes Buchner - 2016 Member of Advisory Board
Gerhard Schaefer - 2013 Member of Advisory Board
Bernhard Hampl 73 2014 Member of Advisory Board
Thomas Siklosi - 2018 Member of Advisory Board
Klaus Rohrig - 2020 Member of Supervisory Board
Wolfgang Essler - 2023 Member of the Supervisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

FYB Comments

Write your thoughts about Formycon AG
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email